Pathogenesis and inflammaging in MDS [MDS Professional Report]
Dr. Moshe Mittelman is hosting the world-leading expert Dr. Michael Savona and they have an attractive conversation on several mechanisms in...
Radio and PodcastLive Radio & Podcasts
Health
MDS Professional Report
This podcast series provides important up-to-the-minute information on MDS including diagnosis, treatment and clinical research.The explosion of information on MDS forces us to seek novel, a...
Episodes
13 episodes
Treatment of lower-risk MDS [MDS Professional Report]
Prof. Uwe Platzbecker from Leipzig and Prof. Moshe Mittelman from Tel-Aviv in an interesting conversation on the various available therapeut...
Treatment for Higher-risk MDS [MDS Professional Report]
Prof. Nicolaus Kröger from Hamburg and Prof. Moshe Mittelman from Tel-Aviv, in a stimulating conversation on the various therapeutic modalit...
Update on Higher-Risk MDS - Lessons from 2023 ASH [MDS Professional Report]
Dr. Nicolaos Papadantonakis from Emory Atlanta and Dr. Moshe Mittelman from Tel-Aviv, describe several updated abstracts from 2023 ASH with...
New trials to address the anemia of lower-risk MDS [MDS Professional Report]
Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss trials presented in American Society of He...
Transfusions and quality of life [MDS Professional Report]
Prof. Rena Buckstein from Toronto, and Prof. Moshe Mittelman from Tel-Aviv discuss issues related to RBC transfusions, the hemoglobin thresh...
Bone marrow failure disorders in childhood [MDS Professional Report]
Prof. Akiko Shimamura of Harvard Medical School, Boston, a world known expert of pediatric hematology discusses with Prof. Guillermo Sanz ,o...
The role of genetics in MDS management [MDS Professional Report]
Drs. Rafael Bejar (San Diego) and Moshe Mittelman (Tel Aviv) discuss several papers highlighting the role of genetics in MDS diagnosis, foll...
MDS in ASH 2021 – Are we already in the molecular era? [MDS Professional Report]
Drs. Moshe Mittelman, of The Tel Aviv Sourasky Medical Center, and Drorit Merkel, of the Sheba Medical Center, both from Tel Aviv University...
Do immune check inhibitors have a role in the treatment of higher-risk MDS? [MDS Professional Report]
Chien Aza – Pembro - BJH The combination of azacitidine and pembrolizumab may be a potential effective regimen for patients with higher-risk...
Will Venetoclax Become The New Standard? [MDS Professional Report]
We will discuss the addition of venetoclax to hypomethylating agents in the treatment of advanced myeloid neoplasms, especially higher-risk...
Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report]
PAPER 1Authors: Vijenthira A. et al. (Princess Margaret, Toronto)Title: Outcomes of patients with hematologic malignancies and COVID-19: a s...
TP53 mutations – were they born equal [MDS Professional Report]
Bernard E et al: In the first presented study, Dr. Elza Bernard and colleagues deliver an important lesson about the high-risk mutation TP53...